**INTRODUCTION**

Currently, there are insufficient data to propose the optimum interaction between nutrition and COVID-19. Thus, it is appropriate to collect all available data in one piece as a door for more cohort studies and experimental research. Coronaviruses (CoVs) are large family viruses that cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. Nutrition is one of the host factors that correlated with variations in influenza morbidity and mortality [1]. The adaptive immune response to infection is multi-faceted and complex, and it involves a variety of cell types and factors such as chemokines, cytokines, enzymes, and hormones [1-3]. The effect of vitamin supplements on immunity not only is difficult to measure but can also involve affecting one component of the immune system but not another. The main way to boost immunity against infections is to maintain personal hygiene, adequate nutritional intake, and a healthy lifestyle [6, 7]. By the time the very first cases of COVID-19 were identified in many countries, it was already clear that certain groups were at greater risk of serious illness, and possibly death, than others. The most susceptible people include subjects with chronic lung diseases, immunocompromised people, heart diseases, diabetes, liver diseases, chronic kidney disease, obesity, and neurological disorders. COVID-19 is a new disease and there is limited evidence regarding risk factors for severe disease. Based on currently available knowledge and clinical expertise; there is no clear picture of this virus. The aim of this paper is to review the latest scientific evidence on the interaction between COVID-19 and nutrition.

**METHODOLOGY**

Google Scholar search engine was used to gather information relating to Coronavirus, COVID-19, nutrition, vitamin supplements, pre-existing diseases, and nutritional care management. The studies were written in English. The period of literature age has extended from the inception of the search engine to the mid of April 2020. The search generated about 319 sources, of which 70 sources were used. These 70 articles were considered relevant because they answered the objectives of the review. The library databases such as PubMed and MEDLINE were also used during the study.

**DISCUSSION**

**Coronavirus disease 2019 (COVID-19)**

COVID-19 appeared in Wuhan in December 2019, the capital of Hubei province, China. COVID-19 is an RNA caused by an anew emerged zoonotic coronavirus [1]. A positive-sense wrapped single-stranded RNA virus; named Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has been insulated from a patient with pneumonia, and attached to the cluster of acute respiratory illness cases from Wuhan. COVID-19 is spread from human to human by droplets coughed or resired by infected persons and by
Nutritional management in ICU patients infected with COVID-19

Retrospective analysis of data available on the 1918 influenza pandemic showed that disease severity may result in worsening of nutritional status with malnutrition and related complications. Adequate nutrient intake assessment is recommended during treatment for monitoring oral nutrition supplements, enteral nutrition and to detect if oral route is insufficient. Most of studies that have been conducted on SARS-CoV and MERS-CoV new crown viruses recommended the importance of applying a nutritional assessment protocol according to ESPEN guidelines to prevent and to address COVID-19 (not yet published) [15, 16]. Table-1 shows the possible nutrition intervention according to oxygen support therapy and ICU setting.

### Table-1: Nutrition intervention according to oxygen support therapy and ICU setting

| Setting          | ICU IST Day  | > 2Day                      |
|------------------|--------------|-----------------------------|
| No response with GIT disorders | Prefer early enteral feeding. | -No response with GIT disorders start parenterally |
| Nutrition        | O2 therapy and M.V | FNC followed by M.V  | Minute Volume “MV”  |
| Intervention     |               |                             |
|                  | -Screening to detection malnutrition. | Define energy and protein target |
|                  | -Define energy and protein target | In case of FNC or NIV, administer energy/protein orally or enterally and if not possible parenterally |

The enteral nutrition Orogastric feeding / Nasogastric feeding should be started during the first 24-48 hours of admission. For highly inadequate implementation of enteral nutrition which may result in patient starvation particularly in the first 24 hours of ICU stay and higher risk of malnutrition and associated complications; the peripheral parenteral nutrition may be therefore used under these conditions [17]. Overlooking administration of adequate calorie-protein rest on viral and host factors. Amongst the host factors correlated with variations in influenza morbidity and mortality age, cellular and humoral immune responses, genetics and nutrition [10]. Malnutrition and famine were associated with high disease severity and was related to mortality also in the younger population. Under-nutrition remains a problem for viral pandemics of the twenty-first century and beyond. Indeed, chronic malnutrition was thought to have contributed to the high morbidity and mortality seen in Guatemalan children during the 2009 influenza pandemic [11]. According to the recent European Society Parenteral and Enteral Nutrition (ESFEN) guidelines on nutritional therapy in Intensive Care Unit (ICU) and the respiratory therapy stages; the nutritional management is guided by the patient’s condition [12]. The nutritional management should consider the respiratory support allocated to the ICU patients to prevent the occurrence of malnutrition. As it is know not all the COVID-19 patients admitted to ICU need to intubated to ensure the successful oxygenation, some patients will placed on Non Invasive Ventilator ((NIV)) or Flow Nasal Cannula ((FNC)) / High Flow Nasal Cannula (HFNC) to monitoring their thermodynamical state especially oxygen statues [11]. Limited studies described the implementation of nutritional support when NIV or FNC / HFNC techniques are used. Nevertheless, limited evidence indicated that the amount of calories and proteins intakes may be inadequate to achieve the patients’ requirements and will not prevent malnutrition occurrence [13, 14]. comparing to patients whose intubated and ventilated on Mechanical Ventilator, most studies confirmed that the importance implementation of nutritional support when patient on intubation, and this is in agreement with ESPEN guidelines in ICU. ESPEN also has critical care nutrition specific guidelines and just produced a new paper that does address COVID-19 (not yet published) [15, 16]. Table-1 shows the possible nutrition intervention according to oxygen support therapy and ICU setting.

© 2020 Scholars Journal of Applied Medical Sciences | Published by SAS Publishers, India
decrease the possibility of malnutrition in ICU settings. Although no specific guidance for COVID-19 virus disease has been identified, the ESPEN guideline have recommended using the nutritional management to any other ICU patient admitted with pulmonary compromise [18, 19]. In a recent review about potential interventions for novel coronavirus based on the Chinese experience authors suggested that the nutritional status of each infected patient should be screened and evaluated before the administration of general treatments [20]. Currently, there is no specific nutrition intervention strategy for COVID-19 has been fully tested for efficacy, but as authors recommend following the previously guidelines.

At present, the first stage, of nutritional intervention for COVID-19 case include nutritional risk screening Nutrition Risk Screening 2002 (NRS-2002) [21], nutritional risk score for critically ill patients (NUTRIC score), or extra tools such as Malnutrition Universal Screening Tool (MUST) for patients affected with COVID-19 to prevent and management the malnutrition. Therefore, an early enteral nutritional support should commence within 24 to 48 hours. Post-pyloric feeding will be favored when aspiration risk is high, age more than 70 years, consciousness level affected, prone position, gastrosophageal reflux and a single load of enteral nutrition. The most important macronutrients requirements for COVID-19 patients in ICU are energy and proteins. The energy expenditure (EE) should be determined to evaluate energy needs by using indirect calorimetry when available. Isocaloric nutrition rather than hypocaloric nutrition can then be progressively implemented after the early phase of acute illness. If calorimetry is not available, VO2 (oxygen consumption) from pulmonary arterial catheter or VCO2 (carbon dioxide production) derived from the ventilator will give a better evaluation on EE than predictive equations. If predictive equation cannot be used for any cause the indirect method should be conduct 15-20 kcal/kg actual body weight (ABW)/day (70-80% of needs). In state, the refeeding syndrome risk is present suspect to start at 25% of caloric goal with slow increase, with frequent monitoring of serum phosphate, magnesium and potassium levels [22]. Hypocaloric nutrition should be administered in the early phase of inflammatory (acute illness) with raises up to 80–100% after three days. If predictive equations are used to estimate the energy need, hypocaloric nutrition (below 80% estimated needs) should be preferred over isocaloric nutrition for the first week of ICU stay due to reports of overestimation of energy needs [23]. During critical illness the protein requirement starting from 1.3 g/kg ABW/day and it can be increased progressively according to health statuses. Considering the importance of preserving skeletal muscle mass and function and the highly catabolic conditions related to disease and ICU stay. Additional strategies may be considered to enhance skeletal muscle anabolism. In particular, controlled physical activity and mobilization may improve the beneficial effects of nutritional therapy [22]. Several studies have been done about the role of carbohydrate and fat in accelerate the weaning time form mechanical ventilator for patients with respiratory diseases [24-26]. In 2014 Saour Faramawy [27] concluded that, the combustion of 1000 calories of the high fat formula result in the production of 173.6 liters of CO2, in contrasts with the 186 liters of CO2 produced from 1000 calories of the standard feed mainly carbohydrate. Another study has been done in 1989 by Al-Saady showed that, the patients who received high fat formula spent 62 hours less time on ventilator than whose receive high carbohydrate formula. It seems that the high fat, low carbohydrate enteral formula appears to be beneficial with COVID-19 patients undergoing artificial ventilation. According to Society of Critical Care Medicine and ASPEN and North American societal guidelines [28, 12, 30]; it should be that start with a standard EN isotonic, high protein formula (1 kcal/ml or 1.5 kcal/ml) and the flow rate started slowly 10-20 ml/h by using continuous route in medical stability. Maintain trophic rate with worsening hemodynamics case during 5 to 7 days and if patient unable to progress during this period start parenteral nutrition earlier. If parenteral nutrition is advised by dietitian in the first week of ICU stay during the acute inflammatory phase of COVID-19, important step should be taken with pure soybean lipid emulsions and check the serum triglyceride after 24 hours of starting lipid emulsion containing formula. Nutrition intervention and management needs to be set as an essential part of the COVID-19 patients’ treatment plan [31, 32].

**Vitamins Supplements and COVID-19**

Immunological response to an infection is not static; initial stages of antigenic stimulation to the later stages of disease development can undergo changes in the characteristics of the response [4, 33]. Therefore the effect of supplements on immunity not only is difficult to measure but can also involve affecting one component of the immune system but not another [34]. Some protective measures can effectively prevent SARS-CoV-2 infection, such as improving personal hygiene, wearing medical masks when needed, good ventilation and adequate rest [35]. However, patients with current diseases, especially chronic diseases such as diabetes, hypertension, coronary heart disease and cancer, are more prone to SARS-CoV-2 infection and its poor prognosis, disease status and sometimes ongoing treatment by these vulnerable group leads to having a lower systemic immunity, “therefore, it is particularly important to enhance self-resistance” Studies have reported that vitamin C; under certain conditions, may lower the susceptibility of lower respiratory tract infection COVID-19 may cause lower respiratory tract infection. Therefore, a moderate amount of vitamin C supplementation has been suggested as a method to prevent COVID-19 [36-39]. Though no conclusive evidence are available and safety
is questionable, high-dose of intravenous vitamin 
C has been recommended for treatment of early stages
COVID-19 pneumonia [40]. Vitamin D and E have been suggested to enhance resistance to SARS-CoV-2, backed by the relationship found between vitamin D and vitamin E deficiency in cattle and their susceptibility toward the infection from bovine coronavirus [41]. However, due to the complexity of innate and adaptive immune responses to antigenic stimulation, it is difficult to pinpoint the overall effect of vitamin D during infection. This complexity sometimes results in different results in vitro compared with in vivo studies [42]. In several observational studies, lower 25(OH) D serum levels were associated with increased risk of respiratory infection in adults, 25(OH) D deficiency has also been connected to increased severity of acute lower respiratory infection in children and mortality from pneumonia in adults [43, 44]. Vitamin D is believed to reduce risk of infection through multiple mechanisms, including inducing defenses and cathelicidins that reduce viral replication rates and lower pro-inflammatory cytokines concentrations, which produce the inflammation induced pneumonia, as well as increasing concentrations of anti-inflammatory cytokines. Several clinical trials and observational studies reported that vitamin D supplementation reduced the influenza risk [45-47], while others did not [48, 49]. Available evidence supporting the role of vitamin D in reducing risk of COVID-19 includes 1-that the outbreak occurred in winter, during which 25-hydroxyvitamin D (25(OH)D) concentrations are lowest [50]. The number of cases near the end of summer in the Southern Hemisphere are low, 3-deficiency of vitamin D was found to contribute to acute respiratory distress syndrome, and 4-case fatality rates increase with chronic disease comorbidity and with age, both of which are associated with lower 25(OH)D concentration. To reduce the risk of infection, Grant and colleagues recommend that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d [51-53]. Aiming to raise 25(OH)D concentrations above 40-60 ng/mL (100-150 nmol/L). For treatment of people who become infected with COVID-19, the authors recommend higher vitamin D3 doses. Large population studies and randomized controlled trials should be conducted to evaluate these recommendations [54, 55].

Existing co-morbidities and covid-19

The presence of existing co-morbidities is associated with poorer clinical outcome in patients with COVID-19 [56]. In a study of 1099 COVID-19 laboratory confirmed patients, 261(23.7%) patients reported having at least one comorbidity, most commonly are diabetes, hypertension and coronary heart disease, in addition 223 (2.1%) of these patients had hepatitis B infection [57]. Those with severe case presentations were more likely to have hepatitis B infection (2.4% versus 0.6%). Abnormal liver function tests, including elevated alanine aminotransferase, aspartate aminotransferase, and total bilirubin were noted [57]. Possible explanations to liver abnormalities in patients with COVID-19 are viral infection in liver cells [1], systemic inflammation and drug toxicity [58]. Cancer patients infected with COVID-19 were observed to have a higher risk of severe events [59]. Patients with cancer are considered more susceptible to infection as a result of their immunocompromised status resulting from anticancer treatments and malignancy.

Malnutrition in critically ill patients is associated with poor outcomes, including impaired wound healing, higher rates of nosocomial infections, and all-cause mortality. Nutritional status of patients admitted to the intensive care unit (ICU) is influenced by both chronic and acute starvation, but also by the severity of the underlying pathophysiological processes leading to ICU admission. This typically induces a marked catabolic response leading to rapid loss of lean body mass, varying from 5% in single-organ failure to 25% in multi organ dysfunction syndrome (MODS), during the first 10 days after ICU admission. Nutritional therapy can improve outcomes associated with malnutrition in critically ill patients. To identify ICU patients most likely to benefit from nutritional support, validated tools are required. Food safety and hygiene is a significant component during food preparation and serving to Covid-19 patients. It is required to use personal hygiene practices against contamination of food, food-contact surfaces, and food packaging and serving [31]. Malnutrition and weight loss is a frequently occurring complication in patients’ pulmonary disease and it is a determining factor of functional capacity, health status and mortality. Malnutrition is a consequence of increased energy requirements that are not balanced by dietary intake. Both metabolic and mechanical inefficiency contribute to elevated total daily energy expenditure. Alterations in anabolic and catabolic mediators resulting in an imbalance between protein synthesis and protein breakdown may cause a disproportionate depletion of fat-free mass in some patients. Nutritional support is indicated for depleted patients with respiratory diseases because it provides not only supportive care, but direct intervention through improvement in respiratory and peripheral skeletal muscle function and in exercise performance. A combination of oral nutritional supplements and exercise or anabolic stimulus appears to be the best approach to obtaining significant functional improvement. Patients responding to this treatment even demonstrated a decreased mortality. Furthermore, weight loss and malnutrition opens the door of infection reoccurrence Poor response was related to the effects of systemic inflammation on dietary intake and catabolism [30-32].

Dietary management of pre-existing diseases has been suggested as a strategy to minimise the potential risk of SARS-CoV-2 infection in conditions
such as irritable bowel syndrome, Crohn’s and Colitis [60-62]. World Health Organizations, dietetic associations and dietitians have been calling for patients with pre-existing conditions to continue abiding to their dietary advice and nutritional therapy steps received from their dietician if tested positive for COVID-19 [63-66] and ASPEN has released a nutritional guideline for patients covering at home [67-69].

**Competing interests:** Authors have declared that no competing interests exist.

**CONCLUSION**

Nutritional management in ICU patients infected with COVID-19, vitamin supplements and COVID-1, and the comorbidity spectrum of nutrition related conditions and their impact on outcome of COVID-19 and treatment remains largely unknown. More data need to be analysed on the impact of nutritional status and dietary modification on COVID-19. In order to more precisely ascertain the risk of SARS-CoV-2 infection in patients with existing comorbidities, and to predict their prognosis.

**REFERENCES**

1. Saif LJ, Wang Q, Vlasova AN, Jung K, Xiao S. Coronavirus. Diseases of swine. 2019 Jun 3:488-523.
2. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Journal of Pharmaceutical Analysis. 2020 Mar 5.
3. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 72.
4. Maruyama T, Fujisawa T, Suga S, Nakamura H, Nagao M, Taniguchi K, et al. Outcomes and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy: a prospective multicenter cohort study. Chest 2016;149:526e34.
5. Peeri NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, Baghbanzadeh M, Aghamohammadi N, Zhang W, Haque U. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. International journal of epidemiology. 2020 Feb 22.
6. Sohrabí C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020 Feb 26.
7. Zavascki AP, Falci DR. Clinical Characteristics of Covid-19 in China. World. 2020 Mar 27;727:33.
8. Short KR, Kedzierska K, van de Sandt CE. Back to the future: lessons learned from the 1918 influenza pandemic. Front Cell Infect Microbiol 2018 Oct 8;8: 343.
9. Terzi N, Darmon M, Reignier J, Ruckly S, Garrouste-Orgeas M, Launette A, et al. OUTCOMEERA study group. Initial nutritional management during noninvasive ventilation and outcomes: a retrospective cohort study. Crit Care 2017;21:293. https://doi.org/10.1186/s13054-017-1867-y.
10. Frat JP, Thille AW, Mercat A, Giraud C, Ragot S, Perbet S, et al., FLORALI Study Group; REVA Network. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372:2185e96.
11. Singer P, Blaser AR, Berger MM, Alhazzawi W, Calder PC, Cesaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019;38:48e79.
12. Gomes F, Schuetz P, Bounoure L, Austin P, Ballesteros-Pomar M, Cederholm T, et al. ESPEN guideline on nutritional support for polymorbid internal medicine patients. Clin Nutr 2018;37:336e53.
13. Volkert D, Beck AM, Cederholm T, Cruz-Jentoft A, Goisser S, Hooper L, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr 2019;38:10e47.
14. American Society of Parenteral and Enteral Nutrition http://www.nutritioncare.org/COVID19/
15. World Health Organization. Regional Office for Europe, data and statistics on obesity. http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics. [Accessed 23 March 2020].
16. Hegazi, Wischmeyer. Clinical review: Optimising Enteral Nutrition for critically ill patients—a simple data-driven formula. Critical Care 2011; 15: 234.
17. Megan Boitano. Hypocaloric Feeding of the Critically Ill. Nutr Clin Pract 2006; 21(6): 617-22.
18. Restrepo M. Health Status and the Role of Nutrition on SARS-CoV/Covid-19.
19. Barazzoni R, Bischoff SC, Krznaric Z, Pirluch M, Singer P. Espen expert statements and practical guidance for nutritional management of individuals with sars-cov-2 infection.
20. Anthony PS. Nutrition screening tools for hospitalised patients. Nutr Clin Pract 2008; 23(4): 373-82. https://www.mdcalc.com/nutrition-riskscreening-2002-nrs-2002.
21. Laviano A, Koverech A, Zanetti M. Nutrition support in the time of SARS-CoV-2 (COVID-19). Nutrition (Burbank, Los Angeles County, Calif.).
22. Cintoni M, Rinninella E, Annetta MG, Mele MC. Nutritional management in hospital setting during SARS-CoV-2 pandemic: a real-life experience. European Journal of Clinical Nutrition. 2020 Apr 6:1-2.
23. Mesejo A, Acosta JA, Ortega C, Vila J, Fernández M, Ferreres J, Sanchis JC, López F. Comparison of a high-protein disease-specific enteral formula with a high-protein enteral formula in
hyperglycemic critically ill patients. Clinical Nutrition. 2003 Jun 1;22(3):295-305.
24. Lanken PN, Terry PB, DeLisser HM, Fahy BF, Hansen-Flaschen J, Heffner JE, Levy M, Mularski RA, Osborne ML, Prendergast TJ, Rocker G. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. American journal of respiratory and critical care medicine. 2008 Apr 15;177(8):912–27.
25. Nava S, Ambrosino N, Clini E, Prato M, Orlando G, Vitacca M, Brigada P, Fracchia C, Rubini F. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease: a randomized, controlled trial. Annals of internal medicine. 1998 May 1;128(9):721-8.
26. Faramawy MA, Allah AA, El Battrawy S, Amer H. Impact of high fat low carbohydrate enteral feeding on weaning from mechanical ventilation. Egyptian Journal of Chest Diseases and Tuberculosis. 2014 Oct 1;63(4):931-8.
27. Al-Saady NM, Blackmore CM, Bennett ED. High fat, low carbohydrate, enteral feeding lowers PaCO2 and reduces the period of ventilation in artificially ventilated patients, Intensive care medicine. 1989 Jul 1;15(5):290-5.
28. McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B, Ochoa JB, Napolitano L, Braga M, Carli F, Drover JW, Flum D, McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P, Taylor B, Ochoa JB, Napolitano L, Braga M, Carli F, Drover JW, Flum D, Kozar R, Martindale RG, Heyland DK, Braga M, Carli F, Drover JW, Flum D, Gramlich L, Herndon DN, Ko C. Summary points and consensus recommendations from the North American Surgical Nutrition Summit. Journal of Parenteral and Enteral Nutrition. 2013 Sep;37:99S-105S.
29. Elfagi S, Nouh F, Omar M, Elramli S. Malnutrition and New Crowns. International Journal of current multidisciplinary studies. 2019 Agus;
30. Elfagi S, Nouh F, Omar M, COPD Nutrition Practical Guidelines. Journal of nutrition and food sciences. 2020; 2(2):2663-7308.
31. Nouh F, Elfagi S, Omar M. Corona virus: the Paradox between Food Insecurity and Weight Gain. EAS Journal of Nutrition and Food Sciences; 2(2); 2020.
32. Bikle DD. Vitamin D and the immune system: role in protection against bacterial infection. Curr Opin Nephrol Hypertens. 2008;17:348–52.
33. Cameron MJ, Kelvin DJ. Cytokines, chemokines and their receptors. Ma- dame Curie Bioscience Database. Austin (TX): Landes Bioscience; 2000.
34. Hughes DA, Norton R. Vitamin D and respiratory health. Clin Exp Immunol. 2009;158:20-5.
35. Lee N, Wong CK, Chan PK, Chan MC, Wong RY, Lun SW, Ngai KL,Lui GC, Wong BC, Lee SK, et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS ONE. 2011;6:e26050.
36. Maria E. Sundaram and Laura A. Coleman. Vitamin D and Influenza. American Society for Nutrition. Adv. Nutr. 3: 517–525, 2012
37. Hou W, Gibbs JS, Lu X, Brooke CB, Roy D, Modlin RL, Bennink JR, Yewdell JW. Viral infection triggers rapid differentiation of human blood monocytes into dendritic cells. Blood. 2012;119:3128–31.
38. Kaminski MM, Ohnemus A, Cornitescu M, Staeheli P. Plasmacytoid dendritic cells and TLR7-dependent signaling promote efficient protection of mice against highly virulent influenza A virus. J Gen Virol. 2012;93:555-9.
39. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of 2019 novel coronavirus infection in China. 2020:2020.02.06.20020974.
40. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020.
41. Li-sheng W, Yi-rwu W, Da-wei Y, Qing-quan L. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence, International Journal of Antimicrobial Agents, 2020.
42. Hemila H. Vitamin C intake and susceptibility to pneumonia. Pediatr Infect Dis Journal, 1997;16:836-7.
43. Erol, Adnan. High-dose intravenous vitamin C treatment for COVID-19. 2020. 31219/osf.io/p7ex8.
44. Nonnecke BJ, McGill JL, Ridpath JF, Sacco RE, Lippolis JD, Reinhardt TA. Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. J Dairy Sci. 2014;97:5566-79.
45. McNally JD, Leis K, Matheos LA, Karuananyake C, Sankaran K, Rosenberg AM. Vitamin D deficiency in young children with severe acute lower respiratory infection. Pediatr Pulmonol. 2009;44:981–8.
46. Inamo Y, Hasegawa M, Saito K, Hayashi R, Ishikawa T, Yoshino Y, Hashimoto K, Fuchigami T, Serum vitamin D concentrations and associated severity of acute lower respiratory tract infections in Japan: anese hospitalized children. Pediatr Int. 2011;53:199–201.
47. Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ. Vitamin D, in- nate immunity and
outcomes in community acquired pneumonia. Respirology. 2011;16:611–6.

49. Grant WB., Lahore H., McDonnell SL., Baggerly CA., French CB., Aliano JL., Bhattachar JP., Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020 Apr 2;12(4). pii: E988. doi: 10.3390/nu12040988.

50. Urashima M., Segawa T., Okazaki M., Kurihara M., Wada Y., Ida H., Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr. 2010;91:1255–60.

51. Aloia JF., Li-Ng M., Re: Epidemic influenza and vitamin D. Epidemiol Infect. 2007;135:1095–6;

52. Yamschikov AV., Desai NS., Blumberg HM., Ziegler TR., Tangpricha V., Vitamin D for infections: a systematic review of randomized controlled trials. Endocr Pract. 2009;15:438–49

53. Kriesel JD., Spruance J., Calcitriol (1,25-dihydroxy-vitamin D3) coadministered with influenza vaccine does not enhance humoral immunity in human volunteers. Vaccine. 1999;17:1883–8.

54. Cooper C., Thorne A., Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults. HIV Clin Trials. 2011;12:275–6.

55. Avenell A., Cook JA., MacLennan GS., MacPherson GC., Vitamin D supplementation to prevent infections: a sub-study of a randomized placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing. 2007;36:574–7.

56. Mao R., Liang J., Shen J., Ghosh J., et al, Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet 2020 (5): 426-428

57. Guan W., Ni Z., Hu Y., et al., Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; published online Feb 28. DOI:10.1056/NEJMoA2002032.

58. Zhang C., Shi L., Wang FS., Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; published online March 4. https://doi.org/10.1016/S2468–1253(20)30057–1.

59. Liang W., Guan W., Chen R., et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; published online Feb 14. DOI:10.1016/S1470–2045(20)30096–6.

60. Malnutrition Chinese Society of IBD. Managing IBD patients during the outbreak of COVID-19. Chin J Dig 2020; 40: E001.

61. Crohn’s Colitis Foundation. What IBD patients should know about the 2019 novel coronavirus (COVID-19). https://www.crohnsandcolitis.org.uk/news/updated-wuhan-novel-coronavirus-advice (accessed March 3, 2020).

62. Crohn’s & Colitis UK. Novel coronavirus (COVID-19) advice. https://www.crohnsandcolitis.org.uk/news/updated-wuhan-novel-coronavirus-advice (accessed March 3, 2020).

63. Dietitians of Canada. Advice for the general public about COVID-19. https://www.dietitians.ca/News/2020/Advice-for-the-general-public-about-COVID-19.(accessed April 15, 2020).

64. World Health Organisation, Nutrition advice for adults during the COVID-19 outbreak. http://www.eatright.org/coronavirus-outbreak.html (accessed April 15, 2020).

65. Academy of Nutrition and Dietetic, Coronavirus (COVID-19). https://www.eatright.org/coronavirus. (accessed April 15, 2020).

66. Elfagi S., Nouh F., Omar M., Libyan Family Nutritional Guideline regarding Coronavirus and COVID-19. Access online [17.4.2020]; available from ; http://www.cqund.com.ly/index.php/office-activities.

67. Elfagi S., Nouh F., Omar M., Libyan COVID-19 Patients’ Nutritional Guideline. Access online [17.4.2020]; available from ; http://www.cqund.com.ly/index.php/office-activities.

68. Demling RH., Nutrition, anabolism, and the wound healing process: an overview. Eplasty. 2009;9:e

69. Reithner L., Insensible water loss from the respiratory tract in patients with fever. Acta Chir Scand. 1981;147(3):163-167.